PESSINA, Achille
 Distribuzione geografica
Continente #
NA - Nord America 1.065
EU - Europa 447
AS - Asia 322
AF - Africa 3
SA - Sud America 3
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 1
Totale 1.843
Nazione #
US - Stati Uniti d'America 1.065
CN - Cina 213
UA - Ucraina 173
FI - Finlandia 67
DE - Germania 66
IT - Italia 62
HK - Hong Kong 54
SG - Singapore 27
IE - Irlanda 26
IN - India 21
FR - Francia 19
GB - Regno Unito 18
SE - Svezia 11
MU - Mauritius 3
RU - Federazione Russa 3
TR - Turchia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
CO - Colombia 2
AR - Argentina 1
AU - Australia 1
CZ - Repubblica Ceca 1
IR - Iran 1
JP - Giappone 1
KZ - Kazakistan 1
NL - Olanda 1
NP - Nepal 1
Totale 1.843
Città #
Woodbridge 135
Fairfield 132
Jacksonville 129
Houston 95
Ann Arbor 66
Chandler 62
Ashburn 59
Wilmington 58
Beijing 56
Hong Kong 54
Princeton 51
Nanjing 49
Cambridge 47
Seattle 42
Helsinki 41
Dublin 26
Nanchang 20
Singapore 16
Des Moines 14
Shanghai 12
Dearborn 10
New York 10
San Diego 10
Shenyang 10
Changsha 8
Milan 8
Tianjin 8
Brescia 7
Hebei 7
Jiaxing 7
Kunming 7
Hangzhou 6
Lanzhou 6
London 6
Haikou 5
Verona 4
Grafing 3
Jinan 3
Ningbo 3
Rome 3
San Francisco 3
Boardman 2
Bogotá 2
Brembate 2
Fuzhou 2
Kocaeli 2
Lancaster 2
Monzambano 2
Mulhouse 2
Seregno 2
Tampa 2
Tempe 2
Villasanta 2
Almaty 1
Amsterdam 1
Andover 1
Asti 1
Bologna 1
Buenos Aires 1
Changchun 1
Chiswick 1
Guangzhou 1
Leawood 1
Melbourne 1
Milanese 1
Noicattaro 1
Norwalk 1
Novokuznetsk 1
Olomouc 1
Orange 1
Paris 1
Plant City 1
Redwood City 1
Sabz 1
San Martino In Rio 1
Sanwal 1
Segrate 1
Sesto Fiorentino 1
Taizhou 1
Tokyo 1
Torino 1
Tucson 1
Varese 1
Viadana 1
Yaroslavl 1
Youngstown 1
Totale 1.355
Nome #
Prospective appraisal of the prevalence of primary aldosteronism in hypertensive patients presenting with atrial flutter or fibrillation (PAPPHY Study): rationale and study design. 126
Vascular remodeling and duration of hypertension predict outcome of adrenalectomy in primary aldosteronism patients. 109
Antihypertensive efficacy of manidipine and enalapril in hypertensive diabetic patients. 104
Independent association of ECG abnormalities with microalbuminuria and renal damage in hypertensive patients without overt cardiovascular disease: data from Italy-Developing Education and awareness on MicroAlbuminuria in patients with hypertensive Disease study. 102
Left ventricular diastolic dysfunction in elderly hypertensives: results of the APROS-diadys study. 101
Chronic kidney disease in hypertension under specialist care: the I-DEMAND study. 98
Comparative effects of the dual ACE and vasopeptidase inhibitor MDL-100,240 and ramipril on hypertension and cardiovascular disease (CVD) in endogenous angiotensin II-dependent hypertension. 92
Confronto tra test al captopril e test d’infusione salina per escludere un adenoma producente aldosterone. 90
Association of renal damage with cardiovascular diseases is independent of individual cardiovascular risk profile in hypertension: data from the Italy - Developing Education and awareness on MicroAlbuminuria in patients with hypertensive Disease study. 89
Prevalence of fetal-type smooth muscle cells in the media of microvessels from hypertensive patients. 78
Different effects of ACE or dual ACE/vasopeptidase inhibition on matrix proteins in small resistance arteries of transgenic rats. 64
Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. SAMPLE Study Group. Study on Ambulatory Monitoring of Blood Pressure and Lisinopril Evaluation. 63
Modificazioni della matrice interstiziale delle piccole arterie di resistenza di ratti transgenici trattati con un ACE o un inibitore delle endopeptidasi neutre. 61
Clinical results of the Verapamil inHypertension and Atherosclerosis Study. VHAS Investigators. 60
Within-patient reproducibility of the ARR for the screening of primary aldosteronism. 59
Body mass index predicts plasma aldosterone concentrations in primary hypertension: Implications for the identification of primary aldosteronism. 57
Effetti di un ACE e di un inibitore delle endopeptidasi neutre sulla matrice interstiziale delle piccole arterie di resistenza di ratti transgenici. 53
Ipertensione con obesità o sovrappeso: un ruolo dell’aldosterone? 52
Bradykinin mediates the anti-hypertensive effect of the novel dual ACE and vasopeptidase (VP) inhibitor MDL-100,240 in TGRen2 rats via B2 receptors 51
L’azione antiipertensiva di MDL-100, 240 coinvolge i recettori B2 per la bradikinina nell’ipertensione arteriosa (IA) Ang II-dipendente. 49
The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. 48
Effects of ACE or dual ACE/vasopeptidase inhibition on matrix proteins in small resistance arteries of transgenic rats 47
Performance diagnostica del tests di infusione salina nella conferma dell’aldosteronismo primario nello studio PAPY. 46
Il rimodellamento vascolare e la durata dell’ipertensione arteriosa predicono la risposta pressoria alla surrenectomia in pazienti con adenoma producenti aldosterone. 44
L’ipertensione (IA) e la malattia cardiovascolare (MCV) dei ratti TGren2 sono mediate dai recettori AT1 della angiotensina (ANG), ma non da quelli dlel’endotelina (ET) attraveso meccanismi indipendenti dagli steroidi corticosurrenalici. 44
Prospective assessment of the diagnostic performance of the saline infusion test in the primary aldosteronism prevalence in hypertensives (PAPY) study 43
ACCURACY IMPROVEMENT OF A IMMS IN AN URBAN SCENARIO 29
Adrenalectomy Lowers Incident Atrial Fibrillation in Primary Aldosteronism Patients at Long Term 2
Totale 1.861
Categoria #
all - tutte 7.770
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.770


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020475 80 9 11 56 22 51 45 51 21 71 27 31
2020/2021279 2 36 1 35 18 35 17 32 51 14 32 6
2021/2022177 4 40 1 6 2 12 11 15 9 18 14 45
2022/2023194 26 0 0 2 23 53 0 25 45 0 8 12
2023/2024207 19 6 4 46 9 14 2 11 56 0 5 35
2024/20252 2 0 0 0 0 0 0 0 0 0 0 0
Totale 1.861